Carregant...
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone
Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension...
Guardat en:
| Publicat a: | Clin Sarcoma Res |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5022265/ https://ncbi.nlm.nih.gov/pubmed/27651889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13569-016-0056-0 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|